28 August 2018 | News
This joint effort of GNG with DMIMS on bio-banking builds upon India’s bio-pharma mission for speedy drug discovery and biomarker studies.
L-R- Dr. Vinod Agarkar (GM- GNG), Ms Supriya Kashikar (COO- GNG), Dr. Ashwin Kashikar (MD- GNG) and Dr. Quazi Sayed Zahiruddin & Team (DMIMS)
GeNext Genomics Pvt. Ltd (GNG) and Research Cell, Datta Meghe Institute of Medical Sciences (DMIMS) have signed a Memorandum of Understanding (MoU) for collaboration to develop Bio-Banking of fully characterized and validated cancer patient tissues and cell lines, first of its kind in the country.
As an innovation-led research-based company in engineered antibodies, GNG with its complete portfolio of monoclonal antibodies and cell culture expertise will not only develop various cancer cell lines along with DMIMS but will also validate and characterize tissue samples.
This joint effort of GNG with DMIMS on bio-banking builds upon India’s bio-pharma mission for speedy drug discovery and biomarker studies. The roadmap is to create a system where Proteomics and Genomics data can be aligned, and research can be expediated for personalized medicine.
With a lot of focus from Govt. of India on translational research, this collaboration will further strengthen the synergies between researchers and the medical fraternity to assess bench to bedside needs. It will also support some of the repurposing of the already available cancer drugs by means of antibody drug conjugates etc.